Postmarketing surveillance For Investigating success in achieving clinical and functional Remission and Sustaining efficacy with Tocilizumab in BIOlogics naive RA patients.
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms FIRST Bio; FIRST-BIO
- Sponsors Chugai Pharmaceutical
- 08 Jul 2016 Status changed from active, no longer recruiting to completed.
- 07 Jul 2016 Planned End Date changed from 28 Feb 2014 to 29 Sep 2014.
- 15 Jun 2015 According to a Chugai pharmaceuticals media release, data from this trial were presented at the European League Against Rheumatism Annual Congress (EULAR 2015).